The development of acute myelogenous leukemia (AML), which is characterized by a block of myeloid dierentiation, is a multi-step process that involves several genetic abnormalities, but the molecular mechanisms by which these genetic alterations cooperate in leukemogenesis are poorly understood. The human chronic myelogenous leukemia (CML) is a model for multi-step leukemogenesis. BCR-ABL, a constitutively active tyrosine kinase, is a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of CML patients. BCR-ABL eciently induces a myeloproliferative disorder (MPD) in mice, but progression to CML blast phase requires additional mutations. The AML1/ MDS1/EVI1 (AME) transcription factor fusion protein, is a product of the human t(3;21)(q26;q22) translocation found as a secondary mutation in some cases of CML during the blast phase. We have previously shown that AME can induce an AML in mice but with a greatly extended latency, suggesting a requirement for additional mutations. Here we demonstrate that AME alone does not block myeloid dierentiation in vivo during the 4-month pre-leukemia stage, yet co-expression of BCR-ABL and AME in mice can block myeloid dierentiation and rapidly induce an AML. Our results suggest that block of myeloid dierentiation and induction of AML involves cooperation between mutations that dysregulate protein tyrosine kinase signaling and those that disrupt hematopoietic gene transcription. Oncogene (2001) 20, 8236 ± 8248.
Introduction
AML is a clonal malignant disease of hematopoietic stem/progenitor cells characterized by a dierentiation block leading to the accumulation of a large number of immature hematopoietic cells in the bone marrow and peripheral blood (Homan et al., 2000) . The uncontrolled growth of malignant cells impairs normal hematopoiesis, leading to anemia, bleeding and increased risk of infection. The development of AML is a multistep process that involves multiple genetic abnormalities (Fialkow et al., 1991; Jacobs, 1991) .
Clonal chromosomal abnormalities are found in approximately two thirds of all AML cases. A number of transcription factors that play important roles in hematopoiesis and organismal development are frequently targeted in AML-associated chromosomal alterations. These include subunits of the core binding factor (CBF) Runx1/AML1 and CBFb, which play crucial roles in de®nitive hematopoiesis (Okuda et al., 1996; Wang et al., 1996) . Knock-in of AML1/ETO (AML1 gene fused to the ETO gene, a zinc-®nger-containing transcription factor, in t(8;21)(q22;q22)-associated de novo AML-M2) or CBFb/SMMHC (CBFb fused to the smooth muscle myosin heavy chain gene (SMMHC) in inv(16)(p13;q22)-associated AML-M4 with eosinophilia subtype) fusion genes in mice resulted in embryonic lethality similar to the AML1 7/7 and CBFb 7/7 mice, suggesting that the fusion genes may function as dominant negative alleles of normal CBF subunits (Castilla et al., 1996; Niki et al., 1997; Okuda et al., 1998; Yergeau et al., 1997) . In cell culture models, AML1/ETO and other AML1-containing fusion genes have been shown to block myeloid cell dierentiation and to immortalize myeloid progenitors (Okuda et al., 1998; Sood et al., 1999; Tanaka et al., 1995a,b; Westendorf et al., 1998) .
However, increasing evidence indicate that expression of the transcription factor type of oncogene alone is not sucient for leukemogenesis in vivo. For example, conditional expression of CBFb/SMMHC in hematopoietic cells and transgenic mice expressing AML1-ETO through the hMRP8 promoter only induces AML when additional genetic abnormalities are induced with a sublethal dose of the chemical mutagen ethylnitrosourea (ENU) (Castilla et al., 1999; Yuan et al., 2001) . We have examined the leukemogenic potential of the AML1/MDS1/EVI1 (AME) fusion protein, a product of the human t(3;21)(q26;q22) translocation found as a secondary mutation in some cases of chronic myelogenous leukemia (CML) during the blast phase, and in therapy-related myelodysplasia and AML (Mitani et al., 1994; Nucifora et al., 1993 Nucifora et al., , 1994 Nucifora, 1997) . We found that expression of AME in mouse bone marrow cells by retroviral transduction induced an AML with a greatly extended latency (5 ± 13 months), indicating that additional genetic abnormalities may have been acquired during leukemogenesis (Cuenco et al., 2000) .
In addition to mutated transcription factors, disruption of signal transduction pathways has also been found in AML. For example, activating point mutations of RAS have been found in approximately 25% of cases of AML (Ahuja et al., 1990; Neubauer et al., 1994) and about 30% of AML cases have an activating internal tandem duplication mutation or point mutation of the FLT3 protein tyrosine kinase receptor (Horiike et al., 1997; Kiyoi et al., 1998; Nakao et al., 1996; Yamamoto et al., 2001; Yokota et al., 1997) . Although it is not known whether all AML cells contain both the transcription factor type and signaling type oncogenes, both disruption of signal transduction and dysregulation of transcription may play important roles in the multistep pathogenesis of AML and a large array of dierent mutations involved in the pathogenesis of AML may aect a few common cellular pathways.
Human CML is a well-studied model of multistep leukemogenesis. CML starts with a benign chronic phase, characterized by increased production of granulocytic cell series. Progression of the disease after 3 ± 5 years to terminal blast phase, often through an accelerated phase, is characterized by accumulation of immature myeloid or lymphoid cells (Goldman, 1997) . The vast majority of CML cases are associated with a t(9;22)(q34;q11) translocation that fuses c-BCR-encoded sequences to a truncated c-ABL gene. The BCR-ABL fusion protein has an elevated protein tyrosine kinase activity and can stimulate multiple signaling pathways (Sawyers, 1999) . Clinical and laboratory studies have demonstrated that BCR-ABL is essential for the induction and maintenance of CML (Daley et al., 1990; Gorre et al., 2001; Heuttner et al., 2000) . However, progression to blast crisis (BCR-ABLpositive AML) involves additional genetic abnormalities (Faderl et al., 1999) .
We and others have shown that expression of BCR-ABL in bone marrow cells by retroviral transduction eciently induces a myeloproliferative disease (MPD) in mice resembling the chronic phase of human CML (Li et al., 1999; Pear et al., 1998; Zhang and Ren, 1998) . The results in this murine CML model are consistent with the clinical observations that secondary mutations in addition to BCR-ABL are required for the progression of CML chronic phase to the blast phase. Since BCR-ABL and AME have been found together in CML patients during the blast/accelerated phase, we wondered whether AME could block hematopoietic dierentiation in vivo and whether BCR-ABL and AME cooperate in inducing an AML. In this study, we examined the direct eect of AME in normal hematopoiesis during the pre-leukemia stage and investigated whether BCR-ABL and AME could cooperate in leukemogenesis using a bone marrow transduction and transplantation approach in mice. We found that AME alone causes certain impairments in hematopoiesis but does not block myeloid dierentiation during the 4-month pre-leukemia stage. However, coexpression of AME and BCR-ABL can block myeloid dierentiation and rapidly induce an AML. These results suggest that blocking of myeloid dierentiation and induction of AML in vivo may require cooperation between mutations that disrupt transcription and mutations that disrupt protein tyrosine kinase signaling.
Results
Expression of the AME fusion protein causes minor impairments in hematopoiesis but does not block myeloid differentiation in vivo during the pre-leukemia stage
To examine the direct eect of AME in hematopoiesis during the pre-leukemia stage, we infected bone marrow cells isolated from 5-¯uorouracil treated mice with MSCV-GFP-IRES-myctag-AME or control MSCV-GFP retrovirus and injected them into irradiated recipient mice. Mice transplanted with GFP+AME-infected bone marrow cells (GFP+AME mice) and control mice transplanted with GFP-infected bone marrow cells (GFP mice) were sacri®ced at 4, 8, and 16 weeks after bone-marrow transplantation (post-BMT). The bone marrow cells from these mice were examined for expression of lineage markers and GFP by¯ow cytometry. As previously described, we determined viral titers for each construct by measuring the amount of infected NIH3T3 cells through quantitation of per cent GFP + cells by¯ow cytometry (Gross et al., 1999) . Our results show that the amount of GFP + cells in the bone marrow of GFP and GFP+AME mice during the pre-leukemia stage was generally proportional to their corresponding viral titers. In two out of three experiments where the GFP retroviral titer was higher than that of GFP+AME retrovirus, the total amount of GFP + cells in the bone marrow was higher in GFP mice than that in GFP+AME mice (Figure 1 left panel) , whereas comparable amounts of GFP + cells in the bone marrow of both GFP and GFP+AME mice were observed in the third experiment where the retroviral titers were matched (data not shown). These results indicate that expression of AME does not signi®cantly aect the overall growth of targeted hematopoietic cells. However, there is one exception: one (mouse #13) of the three GFP+AME mice examined at 16 weeks post-BMT in one experiment has shown a large expansion of GFP + immature hematopoietic cells despite an absence of disease symptoms (Figure 1 right  panel) . We have reported previously that AME induces AML in mice, which die within 5 ± 13 months post-BMT (Cuenco et al., 2000) . The GFP+AME mouse #13 in this experiment appears to represent those mice that have an early disease onset possibly due to an early acquisition of secondary oncogenic mutations.
It is notable that variable levels of GFP expression were observed in both GFP and GFP+AME mouse bone marrow cells, possibly due to dierent integration sites of retroviral vectors in the host chromosomes. The GFP expression patterns in GFP mice persisted through time (Figure 1 ), indicating that there is no selection pressure for cells with particular levels of GFP expression and therefore that GFP has no adverse cellular eect. However, in most of the GFP+AME mice there was a high GFP-expressing bone marrow cell population at 4 weeks post-BMT that gradually disappeared at 8 and 16 weeks post-BMT (Figure 1 left panel) . Interestingly, all GFP+AME mice that developed AML later also consisted of hematopoietic cells with lower GFP expression levels (Figure 1 right panel and data not shown). This result indicates that overexpression of AME, as re¯ected by high expression of GFP, is tolerated in committed hematopoietic progenitor and precursor cells (whose progenies are present within 8 weeks post-BMT) but not in long-term or short-term repopulating hematopoietic stem cells (whose progenies are present at 16 weeks post-BMT). Overexpression of AME is either toxic in hematopoietic stem cells (i.e., non-speci®cally suppresses cell proliferation and/or induces apoptosis) or inhibitory for stem cell dierentiation, possibly due to a strong dominant negative eect of AME on Runx1/AML1 function. However, GFP lo multi-lineage hematopoietic cells were still present at all stages examined (Figure 1 ), indicating that AME, when expressed below a certain level (as is the case in many targeted cells), is not detrimental to hematopoiesis. Multiple hematopoietic lineage GFP + cells were observed in the bone marrow of both GFP and GFP+AME mice (Figure 1) . Most of the GFPpositive Mac-1 + (a myeloid cell marker) cells in GFP and GFP+AME mice at all time points expressed high levels of the Gr-1 marker (a myeloid dierentiation antigen expressed mostly in mature granulocytes) (Figure 1 ), indicating that expression of AME does not block myeloid dierentiation. However, there are subtle dierences in the proportions of dierent lineage marker + cells between GFP and GFP+AME mice. To compare the amount of lineage marker + cells from the two groups, we calculated the ratio of the percentage of lineage marker + /GFP + cells in the total GFP + cell population to that of the percentage of lineage marker + /GFP 7 cells in the total GFP 7 cell population (non-infected normal hematopoietic cells) for each mouse in all three experiments. If ectopic expression of a protein does not aect normal hematopoiesis then the expected ratio described above should be equal or close to one, which is true for the average ratios in the GFP vector control mice (Table 1 ). In contrast, the average ratio of Mac-1 + cells in the GFP+AME mice is generally higher than that of the GFP control mice (Table 1) , in particular at 4 and 16 weeks post-BMT Figure 1 Immunophenotyping of bone marrow cells of GFP and GFP+AME mice. Flow cytometric analysis of the bone marrow cells from representative GFP and GFP+AME mice sacri®ced at 4, 8 and 16 weeks post-BMT. Cells were stained with antibodies to the cell surface markers Mac-1, Gr-1, B220 and Ter119. Staining of c-Kit instead of B220 is shown for the bone marrow cells GFP+AME mouse #13 (right panel). Flow cytometry pro®le shown are 10 and 50% out of 100 000 events collected in GFP and GFP+AME mice, respectively (P-value50.0001). The increase in the proportion of GFP + /Mac-1 + cells in the GFP+AME mice generally correlates with the increase in the proportion of GFP + / Gr-1 + cells (Table 1) . Conversely, the proportion of B220 + cells from the GFP+AME mice tend to be lower than that in GFP mice although statistical analysis resulted in P-values greater than 0.05 (Table  1) . There was also a decreasing trend in the amount of cells stained for the erythroid marker Ter-119 in GFP+AME mice (Figure 1 ). This latter eect may be due to the EVI1 part of AME, since previous study has shown that aberrant expression of EVI-1 blocks normal erythropoiesis (Kreider et al., 1993; Louz et al., 2000) .
In order to examine whether the GFP + /Gr-1 + cells are of normal morphology in both GFP and GFP+AME mice, cytospins of the sorted GFP + /Gr-1 + bone marrow cells from mice at 16 weeks post-BMT were examined ( Figure 2 ). Late myelocytes, metamyelocytes, band neutrophils and some monocytes were all identi®ed (using criteria in Mouse Hematopathology Atlas (Frederickson and Harris, 2000) ) from the GFP + /Gr-1 + bone marrow cells of both GFP ( Figure 2B panels a,b,c) and GFP+AME mice ( Figure  2B panels d and e). Quantitation of these cells demonstrated that the proportion of late myelocytes and metamyelocytes were similar in the GFP and GFP+AME mice, but that the proportion of the maturer band neutrophils was slightly decreased in the GFP+AME mice ( Figure 2C ). The percentage of other types of cells including monocytes and others that could not be accurately identi®ed was also slightly increased in the GFP+AME mice. In one GFP+AME mouse (#11) an increase in eosinophils was also observed. The GFP + /Gr-1 hi cells from GFP+AME mouse #13, which appears to have an early onset of AML, were also sorted. The cytospin preparation of these cells revealed an increase in myelodysplastic cells and a decrease in maturing myeloid cells ( Figure 2B panel f and Figure 2C mouse #13). This result indicates that a small portion of leukemic cells in the GFP+AME mouse #13 can dierentiate into granulocytes but most of them do not mature normally.
The above experiments demonstrate that expression (except for very high level of expression) of AME only caused minor impairments of hematopoiesis, including skewing the ratio of myeloid versus non-myeloid cell lineages, potentially inhibiting lymphopoiesis and erythropoiesis and slightly impairing the maturation of granulocytes. However, expression of AME does not block myeloid dierentiation during pre-leukemia stage. These data further suggest that expansion of GFP+AME cells and block of myeloid dierentiation seen in GFP+AME mice at the AML stage is due to the acquisition of additional genetic abnormalities after a long latent period.
BCR-ABL/GFP and AME can rapidly induce an acute myeloid leukemia in mice
We next investigated whether BCR-ABL and AME can cooperate in blocking myeloid cell dierentiation and in inducing AML. In order to express both genes in the same construct and to facilitate tracking of transplanted bone marrow cells, GFP was fused to the Cterminal region of BCR-ABL (BCR-ABL/GFP) ( Figure  3A) . Expression of both myc-tagged AME and BCR-ABL/GFP proteins were detected by Western blot in BCR-ABL/GFP+AME-infected NIH3T3 cells ( Figure  3B ). However, the amount of BCR-ABL/GFP expressed in BCR-ABL/GFP+AME-infected NIH3T3 cells was approximately twofold lower than that in BCR-ABL/GFP-infected NIH3T3 cells ( Figure 3B ). This would not be detrimental to the system since we have previously shown that twofold lower expression of BCR-ABL due to dierent expression vectors does not aect the ability of BCR-ABL to induce a (Hao and Ren, 2000) . The dierent amounts of AME expressed in AME-infected and BCR-ABL/GFP+AME-infected NIH3T3 cells appear to re¯ect the proportion of infected cells in the population (indicated by GFP expression, Figure  3B bottom panel). These results demonstrate that despite the large genome size of the MSCV-BCR- + cells at dierent stages of maturation. The late myelocytes and metamyelocytes were placed in the same category and monocytes were placed in the`others' category along with cells that cannot be accurately identi®ed ABL/GFP-IRES-myctag-AME retrovirus (about 14 kb), both BCR-ABL/GFP and AME proteins can be expressed in NIH3T3 cells.
We next examined the leukemogenicity of the MSCV-BCR-ABL/GFP-IRES-myctag-AME retrovirus and compared it to MSCV-BCR-ABL/GFP, MSCV-GFP-IRES-myctag-AME and MSCV-GFP retroviruses ( Figure 3A ) in mice by bone marrow transduction/ transplantation. Since the titer of the MSCV-BCR-ABL/GFP-IRES-myctag-AME retrovirus is low (due to its large genome size), titers for the other retroviruses were diluted to approximately match the titer of the BCR-ABL/GFP+AME-retrovirus in these experiments ( Figure 4D ). Under all conditions, BCR-ABL/ GFP, like the wild type BCR-ABL (data not shown), induced a fatal MPD in mice characterized by a massive expansion of granulocytic cells (Figures 4, 5, 6 and Table 2 ). All BCR-ABL/GFP mice with viral titer equal or above 10% GFP + NIH3T3 cells had a disease latency of less than 4 weeks, whereas the disease latency of three out of four BCR-ABL/GFP mice was longer (up to 100 days) when the viral titer was less than 10% GFP + NIH3T3 cells (closer to the titer of the MSCV-BCR-ABL/GFP-IRES-myctag-AME retrovirus) (Figure 4) . By contrast, AME at the lower viral titer conditions (approximately sixfold lower than in previous experiments) failed to induce any disease in mice during the 200-day post-BMT observation period ( Figure 4B,C) . However, the mice that received BCR-ABL/GFP+AME-infected bone marrow cells (BCR-ABL/GFP+AME mice) in three separate experiments developed a fatal disease with median latencies between 46 and 55 days post-BMT (Figure 4) . All of these mice developed symptoms of cachexia, abnormal gait and labored breathing, and either died of disease (15 of 34) or were sacri®ced due to moribund conditions (19 of 34). Interestingly, the disease phenotypes of most of the BCR-ABL/GFP+AME mice were drastically dierent from that induced by BCR-ABL/GFP alone and more similar to that of the GFP+AME mice that developed AML. The slightly longer disease latency of the BCR-ABL/GFP+AME mice compared to BCR-ABL/GFP mice with similar viral titers appears due to an accumulation of immature myeloid cells in hematopoietic organs of BCR-ABL/GFP+AME mice, which may have prevented the development of pulmonary hemorrhages due to a massive in®ltration of granulocytes in the lungs seen in BCR-ABL/GFP alone mice (see below).
The diseased BCR-ABL/GFP+AME mice examined (23 of 34) could be categorized into four groups based on their disease phenotype and latency (Table 2) . Mice belonging to Groups 1, 2 and 3 (15 mice) had a disease latency of less than 60 days, compared to greater than 60 days for Group 4 (eight mice). Most of the diseased mice examined (Groups 1, 2, 4 ± 20 mice) manifested anemia as measured by decreased total blood cell counts and hematocrit levels in the peripheral blood (Table 2 and data not shown). The peripheral WBC counts of these anemic mice varied, but were in general elevated when compared to control GFP mice (Table  2) . Peripheral blood and bone marrow smears of these anemic BCR-ABL/GFP+AME mice showed a large increase of myeloid blast/immature cells compared to BCR-ABL/GFP and GFP control mice ( Figure  5c ,d,g,h versus 5b,f and 5a,e, respectively). Dierential counts of the peripheral blood revealed greater than 30% myeloid blast/immature cells in most of the anemic BCR-ABL/GFP+AME mice (Table 2) , although the mice in Group 2 (4 mice) and one mouse in Group 4 had myeloid blast/immature cell counts between 18 ± 24%. Both symptoms of anemia and increase proliferation of myeloid blast/immature cells are characteristics previously observed in GFP+AME mice transduced with high titer retrovirus that developed AML (Cuenco et al., 2000) . Interestingly, the BCR-ABL/GFP+AME mice in Group 3 (three mice) did not develop anemia and had elevated peripheral WBC counts with granulocyte predominance, indicating that they developed a MPD. However, the development of MPD in this group of BCR-ABL/GFP+AME mice correlates with a loss of AME expression (see below).
Flow cytometric analyses of peripheral blood, bone marrow and spleen of BCR-ABL/GFP+AME mice was performed to con®rm the identity of the leukemic cells. Most of the GFP + WBCs in the peripheral blood ( Figure 6A ) and bone marrow ( Figure 6B ) of BCR-ABL/GFP+AME mice were Mac-1 7/lo /Gr-1 7/lo immature cells, while cells from BCR-ABL/GFP alone mice were mostly GFP + /Mac-1 hi /Gr-1 hi mature granulocytic cells. The increasing amount of Mac-1 7/lo /Gr-1 7/lo immature cells correlates with the increasing quantity of blast cells observed in the dierential counts of the BCR-ABL/GFP+AME mice. Very few, if any, of the GFP + cells in the BCR-ABL/GFP+AME mice were positive for other lineage markers such as B220, CD3/CD4/CD8 and Ter119 (data not shown). However, several diseased BCR-ABL/GFP+AME mice (nine of 23 analysed) also had a signi®cant amount (greater than 10%) of c-Kit + cells (an immature hematopoietic cell marker) in either the peripheral blood or bone marrow or spleen (data not shown). However, these c-Kit + cells were not present in all of the BCR-ABL/GFP+AME mice that have greater than 30% of myeloid blast/immature cells. This is dierent from the GFP+AME mice that developed AML, which contained a larger proportion of c-Kit + cells (Cuenco et al., 2000) . These data con®rm that most of the GFP + WBCs in the diseased BCR-ABL/GFP+AME mice are of immature myeloid lineage and are present in the peripheral blood, bone marrow, and spleen.
Transfer of bone marrow cells from one diseased BCR-ABL/GFP+AME mouse into ®ve irradiated secondary recipients showed that all of the mice developed AML with a latency (60 days) similar to the primary recipient mouse. For unknown reasons, four other BCR-ABL/GFP+AME mice failed to result in the transfer of disease into secondary recipients. The observations described above demonstrate that expression of both BCR-ABL/GFP and AME induces a rapid AML in the majority of recipient mice (15 of 23 examined) that is characterized by anemia and accumulation of immature myeloid cells. The disease phenotype of the BCR-ABL/GFP+AME mice that had greater than 30% myeloid blast/immature cells may correspond the blast phase of human CML, whereas the mice that had 18 ± 24% blast cells may correspond to the accelerated phase of human CML.
Different distribution of neoplastic cells in BCR-ABL/GFP mice versus BCR-ABL+AME mice
Histologic examination of the spleen, liver and lungs of BCR-ABL/GFP mice and BCR-ABL+AME mice was Symbols represent mice that died of disease or sacri®ced due to moribund conditions. The straight line that does not have symbols in (A), (B), and (C) represents GFP vector control mice, and also represents the GFP+AME mice in (B) and (C). All of the GFP and GFP+AME mice were disease-free at 200 days post-BMT. (D) Relative retroviral titer of the constructs in each experiment shown as %GFP + NIH3T3 cells performed to determine how hematological neoplasms aect these organs. As previously shown (Zhang and Ren, 1998), hepatosplenomegaly, attributed to massive extramedullary hematopoiesis and in®ltration of mature granulocytes, was observed in BCR-ABL/GFP mice (Figure 5j ,m,p). The mature granulocytes from the BCR-ABL/GFP mice also massively in®ltrated their lungs (data not shown). In BCR-ABL/ GFP+AME mice splenomegaly (603+132 mg) due to extensive accumulation of myeloid blast/immature cells was found (Figure 5k ,n). In®ltration of myeloid blast/immature cells was also found in livers of BCR-ABL/GFP+AME mice ( Figure 5q ) but was not as extensive as in the spleen of these mice. The most drastic dierence between BCR-ABL/GFP mice and BCR-ABL/GFP+AME mice was the involvement of the lungs. Massive in®ltration of mature granulocytes in the lungs of BCR-ABL/GFP mice seems to be the cause of pulmonary hemorrhages found in these mice, which in turn may account for their rapid death. In contrast, accumulation of immature cells in hematopoietic organs (bone marrow and spleen), due to a block of myeloid dierentiation by coexpression of BCR-ABL/GFP and AME in BCR-ABL/GFP+AME mice resulted in the release of fewer mature granulocytes to the periphery, which may account for the lack of pulmonary hemorrhages and longer survival of these mice.
Expression of both BCR-ABL/GFP and AME proteins is required for development of AML To establish whether both BCR-ABL/GFP and AME proteins are expressed in leukemic cells, Western blot analysis of total spleen lysates from BCR-ABL/ GFP+AME mice that developed myeloid leukemia was performed. Figure 7A shows that BCR-ABL/GFP is expressed in the BCR-ABL/GFP mice and both BCR-ABL/GFP (*220 kd) and myc-tagged-AME (*200 kd) fusion proteins are expressed in most of the BCR-ABL/GFP+AME mice but not in the GFP nd nd *Data above were obtained when BCR-ABL/GFP=AME and BCR-ABL/GFP mice were at moribund conditions or 2 days before death. The numbers of mice were examined from the BCR-ABL/GFP-AME groups were pooled from three experiments. **Median and their ranges are presented. {In general, mice with total blood counts of 42.56 6 cells ml were considered anemic. Hematocrit measurements for some of the anemic mice were 430%. {Only one mouse had 24% myeloid blast cells in this group Figure 5 Accumulation of myeloid blast/immature cells in the peripheral blood, bone marrow, spleen and liver of diseased BCR-ABL/GFP+AME mice. Peripheral blood (a ± d), and bone marrow (e ± h) smears from representative GFP vector mice (a and e), BCR-ABL/GFP mice (b and f), Group 1 BCR-ABL/ GFP+AME mice (c and g) and Group 4 BCR-ABL/GFP+AME (d and h). Histologic examination of spleen (i ± n) and liver (o ± q) sections, stained with hematoxylin and eosin, from GFP mice (i,l,o), BCR-ABL/GFP mice (j,m,p) and BCR-ABL/GFP+AME mice (k,n,q). Panels i,j,k and o,p,q are at 406 magni®cation and l,m,n are at 6306 magni®cation vector control. A truncated AME was expressed in one BCR-ABL/GFP+AME mouse and lack of AME expression was observed in another BCR-ABL/ GFP+AME mouse ( Figure 7C ). The few defects in AME expression correlate with the truncations of the BCR-ABL/GFP+AME proviral DNA detected in the corresponding mice (see below). In general, the level of expression of BCR-ABL/GFP and AME fusion proteins approximately correlated with the proportion of GFP + cells but the BCR-ABL/GFP protein was expressed less in BCR-ABL/GFP+AME mice than that in BCR-ABL/GFP mice, consistent with its expression pattern in NIH3T3 cells infected with respective retroviruses ( Figure 3B ). Both fusion proteins can also be detected in the peripheral blood and bone marrow by Western blot analysis (data not shown).
Southern blot analysis of genomic DNA isolated from the spleen of BCR-ABL/GFP and BCR-ABL/ GFP+AME mice were digested with EcoRI to examine the clonality of the tumor cells. Most of the BCR-ABL/GFP+AME mice contained one to three tumor cell clones, whereas BCR-ABL/GFP mice have at least four clones ( Figure 7D ). The number of tumor cell clones in the BCR-ABL/GFP mice shown here was less than the polyclonal MPD previously shown in BCR-ABL mice (Zhang and Ren, 1998) , perhaps due to the lower retroviral titer used. The quantities of proviral DNAs generally correlated with the percentages of GFP + cells and DNA loading (data not shown). Genomic DNA isolated from the spleen of BCR-ABL/GFP and BCR-ABL/GFP+AME mice was also digested with XbaI, which releases nearly all of the provirus (see Figure 3A) , for examining the integrity of the provirus. Figure 7B demonstrates that most of the BCR-ABL/GFP+AME mice have an intact provirus. However, Southern blot analysis of the spleen of one diseased BCR-ABL/GFP+AME mouse (not included in Table 2 ) showed that its provirus is smaller ( Figure  7B mouse #16 in Exp. #3). Interestingly, Western blot analysis of the spleen cells from this mouse, as described above, show expression of a truncated AME protein (*100 kd instead of 200 kd) but a fulllength BCR-ABL/GFP protein was expressed in this mouse ( Figure 7C mouse #16 ). This mouse suered from an abdominal B-cell lymphoma in addition to symptoms similar to mice in Group 4 with a latency of 114 days post-BMT. This result suggests that the NH 2 -terminal half of AME may still cooperate with BCR-ABL/GFP in blocking myeloid dierentiation and in inducing myeloid leukemia in mice, possibly with a reduced eciency. As mentioned above, one of the BCR-ABL/GFP+AME mice that developed MPD expressed BCR-ABL/GFP but not AME ( Figure 7C mouse #13). Southern blot analysis of this mouse (#13 Exp. #3) and another mouse (#22 Exp. #1), which both belong to Group 3 mice that developed MPD, revealed a truncated BCR-ABL/GFP+AME provirus ( Figure  7B ). Taken together, these data indicate that expression of both BCR-ABL/GFP and AME are required to induce AML.
Discussion
In this study we found that expression of AME in mouse bone marrow cells caused minor impairments of hematopoiesis but did not block myeloid dierentiation during pre-leukemia stage and coexpression of BCR-ABL and AME blocked myeloid dierentiation and induced rapidly an AML in mice. Common features of the disease induced by BCR-ABL/GFP+AME include: (i) anemia; (ii) elevated WBCs in the peripheral blood; (iii) splenomegaly; (iv) accumulation of a large number of myeloid blast/immature cells in bone marrow and blood; (v) acute course of the disease (short interval between the disease onset and death). The variation in disease phenotype and latency of the BCR-ABL/GFP+AME mice may be caused by dierences in the frequency of targeting the appropriate hematopoietic cells during infection due to the lower retroviral titers. Alternatively, additional genetic abnormalities, other than expression of BCR-ABL/ GFP and AME, may be involved in leukemogenesis.
In humans, AML and the blast phase of CML are more aggressive than myeloproliferative disorder Figure 6 Flow cytometry analysis of peripheral blood (A) and bone marrow (B) cells isolated from GFP, BCR-ABL/GFP and BCR-ABL/GFP+AME mice. Cells were stained with Mac-1 and Gr-1 antibodies (MPD). However, BCR-ABL/GFP+AME-induced AML in mice appeared as a less aggressive disease than that induced by BCR-ABL/GFP alone ( Figure  4C ). This dierence seems due to the unusually aggressive disease in mice caused by BCR-ABL/GFP. In mice, BCR-ABL/GFP-induced MPD leads to a rapid and massive in®ltration of mature granulocytes into capillaries of the lungs, which lead to the development of pulmonary hemorrhages ± the most likely cause of the rapid death of BCR-ABL/GFP mice. This phenotype is a drastic dierence between BCR-ABL/GFP-induced MPD in mice and human CML in chronic phase. In contrast to the BCR-ABL/ GFP mice, no pulmonary hemorrhages were found in mice with BCR-ABL/GFP+AME-induced AML. This is most likely due to the fact that the immature leukemic cells in the BCR-ABL/GFP+AME mice are retained in the hematopoietic organs instead of being released to the periphery and in®ltrating the lung. A fundamental dierence between MPD and AML is that myeloid cell dierentiation is blocked in AML but not in MPD. Here we observed that BCR-ABL and AME cooperate to block myeloid dierentiation and rapidly induce an AML. The aggressiveness of BCR-ABLinduced MPD may re¯ect the dierences in anatomy/ physiology of the lungs of mouse and human.
There are some dierences between AML induced by AME alone versus AML induced by BCR-ABL/ GFP+AME. At the terminal stage, Gr-1 is not detectable on leukemic cells from mice with AMEinduced AML, whereas some Gr-1 + cells remain in BCR-ABL/GFP+AME mice. In addition, there is a larger proportion of c-Kit + cells in all diseased AME mice compared to BCR-ABL/GFP+AME mice. These dierences suggest that the additional mutated genes acquired in AME-induced AML may have dierent properties from BCR-ABL.
It has been shown that the CBF subunits Runx1/ AML1 and CBFb are essential for de®nitive hematopoiesis and AML1/ETO and CBFb/SMMHC fusion proteins can function as dominant negative alleles of normal CBF subunits (Castilla et al., 1996 ; Niki et al., Figure 7 Western and Southern blot analysis of spleen cells from BCR-ABL/GFP+AME, BCR-ABL/GFP and GFP mice. The anti-myc (9E10), anti-ABL (AB-3) or anti-dynamin (for loading control) antibodies were used in the Western blot analysis (A and C). The %GFP + cells were analysed using¯ow cytometry. The BCR-ABL/GFP+AME mouse #13 expresses the BCR-ABL/GFP but not AME protein and the BCR-ABL/GFP+AME mouse #16 expresses the full-length BCR-ABL/GFP and a truncated AME protein. (C) The genomic DNA from spleen cells of BCR-ABL/GFP and BCR-ABL/GFP+AME mice were digested with XbaI (B) or EcoRI (D), respectively. The IRES DNA fragment was used as a probe in the Southern blot analysis (B and D). Most of the BCR-ABL/GFP+AME mice have intact provirus except for the BCR-ABL/GFP+AME mouse #13 and #16 in Exp. #3 and the BCR-ABL/GFP+AME mouse #22 in Exp. #1 (B) 1997; Okuda et al., 1996 Okuda et al., , 1998 Wang et al., 1996; Yergeau et al., 1997) . However, the developmental block due to the loss of CBF function seems to be at the level of precursors of the de®nitive hematopoietic stem cell. The eect of AML-associated fusion genes in hematopoietic stem cells and the hematopoiesis thereafter is not clear. In vivo, it has been shown that AME and other AML-associated fusion genes can block granulocytic dierentiation of the IL-3-dependent 32D cell line when stimulated with G-CSF (Okuda et al., 1998; Sood et al., 1999; Tanaka et al., 1995a,b; Westendorf et al., 1998) . However, cultured hematopoietic cell lines harbor various genetic abnormalities. Such in vitro assays may not re¯ect the direct role of oncogenes in hematopoiesis in vivo. For example, expression of BCR-ABL in 32D cells prevented G-CSF-induced dierentiation (Perrotti et al., 1998) but expression of BCR-ABL in bone marrow cells in mice induces a myeloproliferative disorder without blocking cell dierentiation (Zhang and Ren, 1998) . In this report we have shown that expression of AME alone does not block myeloid dierentiation during the 4-month pre-leukemia stage in mice despite causing other impairments in hematopoiesis. This result indicates that blocking myeloid cell dierentiation requires cooperation of two or more aberrant signals. Our results that coexpression of AME and BCR-ABL rapidly induced an AML suggest that cooperation between mutations that dysregulate growth factor receptor signaling and those that disrupt hematopoietic gene transcription may be required to block myeloid dierentiation and to induce AML.
A dierentiation block leading to the accumulation of immature hematopoietic cells characterizes both AML and the blast phase of CML. Development of both of these malignancies may require accumulation of genetic abnormalities that disrupt regulation of cell proliferation, apoptosis and dierentiation. The dierent initiating mutational event ± one with activating signaling proteins and the other with disruption of transcription factors ± may underlie the dierent clinical phenotypes observed. CML manifests a chronic phase seen as a myeloproliferative disorder while in AML-associated genetic abnormalities may be more latent or sometimes induce a myelodysplasia prior to the development of a full-blown AML, depending on the properties of the initial mutated genes. Despite this, the mechanism of multi-step development of both diseases may involve cooperation between transcription and signaling types of oncogenes as well as tumor suppressor genes. Therapies that target cooperating oncogenes/tumor suppressor genes or their corresponding pathways may prove to be eective in treating AML. The rapid AML-mouse model established here should facilitate the study of the molecular mechanisms underlying BCR-ABL and AME-induced leukemogenesis, and the identi®cation of common pathways involved in the pathogenesis of AML. It could also provide a platform for testing new therapies for patients with AML and CML in blast phase.
Materials and methods

DNA constructs
The cDNA of GFP (0.7 kb) was fused to the C-terminal end of the 6.3 kb DNA coding sequence of BCR-ABL using an engineered NotI site on the 3' end of BCR-ABL and the 5' end of GFP. The BCR-ABL/GFP fusion was cloned into the EcoRI site of MSCV and MSCV-IRES-myc tag-AME retroviral vectors that assembled two constructs: MSCV-BCR-ABL/GFP and MSCV-BCR-ABL/GFP-IRES-myctag-AME ( Figure 3A) . The MSCV-IRES-GFP and MSCV-GFP-IRES-myctag-AME used were as described (Cuenco et al., 2000) .
Retrovirus preparation
Helper-free retroviruses were generated by transiently transfecting the retroviral vectors into BOSC-23 cells as described (Gross et al., 1999; Zhang and Ren, 1998) . To estimate viral titers for each construct, we measured the amount of infected NIH3T3 cells by quantitating the per cent GFP + cells by¯ow cytometry (Gross et al., 1999) . In experiments assessing the eects of AME on hematopoiesis during the pre-leukemic stage, the titer of GFP-and GFP+AME-retroviruses were both at 40 ± 50% GFP + cells in one experiment, and 90 ± 99% for GFP-and 60 ± 70% for GFP+AME-retroviruses in two experiments where the titers were not matched. In experiments assessing the leukemogenicity of BCR-ABL/GFP+AME, the titers of all retroviruses used were matched at approximately 10% GFP + cells ( Figure 4D ). This is because the titer of BCR-ABL/ GFP+AME-retrovirus was relatively low due to its large genome size. The retroviral titer of BCR-ABL/GFP+AME was increased by concentrating the retroviral supernatant using VIVASPIN-20 spin concentrator (Vivascience, Inc) for 25 min at 2000 g at 48C. The virus concentrate was sterilized using a 0.22 m ®lter. This method allowed us to raise the viral titer to 20% GFP + cells ( Figure 3B ).
Bone marrow transduction and transplantation
Bone marrow cells from 5-¯uorouracil-treated Balb/C mice were isolated, infected and transplanted into syngeneic recipient mice as previously described (Gross et al., 1999; Zhang and Ren, 1998) . Secondary transplants were performed as previously described (Cuenco et al., 2000) .
Western and Southern blot analysis
Total cell lysates from peripheral blood, bone marrow and spleen of diseased mice were processed for Western blot as in previous study (Cuenco et al., 2000) . Genomic DNA from diseased mice were isolated and digested with XbaI to check proviral integrity and with EcoRI for clonality, and subjected to Southern blot analysis as previously described (Zhang and Ren, 1998), using a 32 P-labeled 0.6 kb IRES DNA fragment as probe.
Blood cell counts, histology and flow cytometry
Peripheral blood counts of recipient mice were counted starting from two weeks after transplantation, twice a week for the duration of the experiment as described (Cuenco et al., 2000) . Peripheral blood and bone marrow smears were stained with Hema 3 (Fisher) for routine identi®cation of cell morphology. Percentage of late myelocytes/metamyelocytes, band neutrophils, eosinophils and other cells including monocytes were calculated by counting the amount of cells in a total of at least 200 cells. Percentage of immature blasts and mature cells in the peripheral blood were also calculated by counting the amount of cells in a total of at least 200 cells. Tissues were ®xed with 4% paraformaldehyde in PBS and processed for paran-embedded sectioning at 5 mm in thickness, followed by staining with hematoxylin and eosin. Cells from peripheral blood, bone marrow, and spleen were processed and stained with PE-conjugated mouse antibodies (Pharmingen) for¯ow cytometry as previously described (Cuenco et al., 2000) . A total of 100 000 events were collected using the FACSCALIBUR (Becton Dickinson) for assessing the eect of AME in hematopoiesis. The GFP+/Gr-1+ bone marrow cells were sorted using MoFlo (Cytomation) and cytospin preparations of these sorted cells were stained with HEMA-3.
